The Role of Missing Killer Cell Immunoglobulin-Like Receptor Ligands in T Cell Replete Peripheral Blood Stem Cell Transplantation from HLA-Identical Siblings

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 2, 2010, Pages 273-280

  Clausen, Johannes ^a   Kircher, Brigitte ^a   Auberger, Jutta ^a   Schumacher, Petra ^a   Ulmer, Hanno ^a   Hetzenauer, Gabriele ^a   Wolf, Dominik ^a   Gastl, Günther ^a   Nachbaur, David ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Allogeneic stem cell transplantation; Human leukocyte antigen; Killer cell imunoglobulin like receptor; Natural killer cell

Indexed keywords

BW4 LIGAND; EPITOPE; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR LIGAND; LIGAND; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOIMMUNITY; ARTICLE; CD34+T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HETEROZYGOSITY; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; SIBLING; T CELL DEPLETION; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, KIR; RECURRENCE; RETROSPECTIVE STUDIES; SIBLINGS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 75149147975     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.021     Document Type: Article

References (40)

1. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
2. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
3. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
4. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172 (2004) 644-650
5. Kroger N., Shaw B., Iacobelli S., et al. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol 129 (2005) 631-643
6. Beelen D.W., Ottinger H.D., Ferencik S., et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 105 (2005) 2594-2600
7. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12 (2006) 828-836
8. Bornhauser M., Schwerdtfeger R., Martin H., et al. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103 (2004) 2860-2861
9. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
10. De Santis D., Bishara A., Witt C.S., et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 65 (2005) 519-528
11. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 12 (2006) 876-884
12. Kroger N., Binder T., Zabelina T., et al. Low number of donor activating killer immunoglobulin-like receptors (KIR) genes, but not KIR-ligand mismatch, prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation 82 (2006) 1024-1030
13. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106 (2005) 4370-4376
14. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
15. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103 (2004) 1521-1526
16. Giebel S., Locatelli F., Wojnar J., et al. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-Cmatched unrelated donor haematopoietic stem cell transplantation. Br J Haematol 131 (2005) 483-486
17. Miller J.S., Cooley S., Parham P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007) 5058-5061
18. Sobecks R.M., Ball E.J., Maciejewski J.P., et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplant 39 (2007) 417-424
19. Sobecks R.M., Ball E.J., Askar M., et al. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 41 (2008) 709-714
20. Clausen J., Wolf D., Petzer A.L., et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigenidentical haematopoietic stem cell transplantation. Clin Exp Immunol 148 (2007) 520-528
21. Fischer J.C., Ottinger H., Ferencik S., et al. Relevance of C1 and C2 epitopes for hemopoietic stem cell transplantation: role for sequential acquisition of HLA-Cspecific inhibitory killer Ig-like receptor. J Immunol 178 (2007) 3918-3923
22. Ludajic K., Balavarca Y., Bickeboller H., et al. KIR genes and KIR ligands affect occurrence of acute GVHD after unrelated, 12/12 HLA-matched, hematopoietic stem cell transplantation. Bone Marrow Transplant 44 (2009) 97-103
23. Yu J., Venstrom J.M., Liu X.R., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell depleted allogeneic hematopoietic cell transplantation. Blood 113 (2009) 3875-3884
24. Stern M., Ruggeri L., Capanni M., et al. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood 112 (2008) 708-710
25. + blood progenitor cells and peripheral blood lymphocytes. Biol Blood Marrow Transplant 10 (2004) 691-697
26. Feuchtinger T., Pfeiffer M., Pfaffle A., et al. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant 43 (2009) 875-881
27. Garrido F., and Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83 (2001) 117-158
28. Verheyden S., Ferrone S., Mulder A., et al. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells. Cancer Immunol Immunother 58 (2008) 855-865
29. Fauriat C., Andersson S., Bjorklund A.T., et al. Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J Immunol 181 (2008) 6010-6019
30. Hansasuta P., Dong T., Thananchai H., et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 34 (2004) 1673-1679
31. Yawata M., Yawata N., Draghi M., et al. MHC class Ispecific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112 (2008) 2369-2380
32. Giebel S., Nowak I., Wojnar J., et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor hematopoietic cell transplantation. Transplant Proc 38 (2006) 287-291
33. Verheyden S., Schots R., Duquet W., and Demanet C. A defined donor-activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 19 (2005) 1446-1451
34. Cook M., Briggs D., Craddock C., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107 (2006) 1230-1232
35. Chen C., Busson M., Rocha V., et al. Activating KIR genes are associated with CMV reactivation and survival after nonT-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 38 (2006) 437-444
36. Kim H.J., Choi Y., Min W.S., et al. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus-host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia. Transplantation 84 (2007) 1082-1091
37. Van der Meer A., Schaap N.P., Schattenberg A.V., et al. KIR2DS5 is associated with leukemia-free survival after HLA-identical stem cell transplantation in chronic myeloid leukemia patients. Mol Immunol 45 (2008) 3631-3638
38. *003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 68 (2007) 128-134
39. Dunbar E.M., Buzzeo M.P., Levine J.B., et al. The relationship between circulating natural killer cells after reduced-intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica 93 (2008) 1852-1858
40. Baron F., Petersdorf E.W., Gooley T., et al. What is the role for donor natural killer cells after nonmyeloablative conditioning?. Biol Blood Marrow Transplant 15 (2009) 580-588